scholarly journals Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma

2011 ◽  
Vol 129 (6) ◽  
pp. 371-379 ◽  
Author(s):  
Adrienne Pratti Lucarelli ◽  
Maria Marta Martins ◽  
Wagner Montor ◽  
Vilmar Oliveira ◽  
Maria Antonieta Longo Galvão ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Normal Epithelium ◽  
Her 2 ◽  
Epidermal Growth ◽  
Cox 2

CONTEXT AND OBJECTIVE: Cyclooxygenase-2 (COX-2) and human epidermal growth factor receptor type 2 (HER-2) are associated with tumorigenesis. Studies have shown that HER-2 can regulate COX-2 expression. The aim of this study was to evaluate the correlation between COX-2 and HER-2 expression in normal breast epithelium and in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) present in the same breast. DESIGN AND SETTING: Cross-sectional study at the Mastology Unit of the Department of Gynecology and Obstetrics, Santa Casa de Misericórdia de São Paulo Hospital. METHODS: COX-2 and HER-2 were detected using immunohistochemistry on 100 tissue fragments. HER-2 > +2 was subjected to fluorescence in situ hybridization (FISH). RESULTS: COX-2 expression was detected in 87%, 85% and 75% of IDC, DCIS and normal epithelium, respectively. HER-2 expression was detected in 34% of IDC and 34% of DCIS. COX-2 in DCIS correlated with HER-2 in IDC (P = 0.049) and DCIS (P = 0.049). COX-2 in normal epithelium correlated with HER-2 in IDC (P = 0.046) and DCIS (P = 0.046). COX-2 in IDC was not associated with HER-2 (P = 0.235). Comparison between COX-2 and HER-2 in DCIS showed that there was a statistically significant difference with regard to nuclear grades II and III and presence of comedonecrosis (P < 0.001). In IDC, there was significant expression with nuclear grades II and III and histological grade II (P < 0.001). CONCLUSIONS: Our findings provide evidence that HER-2 and COX-2 regulate each other

Increased Likelihood of Mastectomy in Human Epidermal Growth Factor Receptor 2-positive Ductal Carcinoma In Situ

2014 ◽  
Vol 80 (10) ◽  
pp. 936-939 ◽  
Author(s):  
Anna Weiss ◽  
Vivi Tran ◽  
Jennifer Baker ◽  
Hasteh Farnaz ◽  
Anne M. Wallace ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Patients with human epidermal growth factor receptor 2 (HER2neu)-positive breast invasive cancer are known to have larger, more aggressive tumors. Little research exists on the relationship between HER2neu status and extent of ductal carcinoma in situ (DCIS). A retrospective review of a single-institution database was performed for patients with DCIS between the years 2002 and 2011. A single blinded breast radiologist reviewed preoperative imaging. Pathology was reviewed for extent of DCIS. Primary outcome was mastectomy. Multivariate logistic regression was used to determine adjusted mastectomy risk. There were 166 cases, 34 HER2neu-positive. HER2neu receptor-positive patients had larger lesions on imaging: 4.0 versus 2.7 cm, by 2.9 versus 1.5 cm ( P = 0.0499 and 0.0182). HER2neu-positive patients with DCIS were more likely than HER2neu-negative to undergo mastectomy than lumpectomy (53 vs 28%, P = 0.006). Pathology revealed a trend toward larger lesions in HER2neu-positive patients (2.96 vs 2.22 cm, nonsignificant). Patients with HER2neu-positive disease were three times more likely to undergo mastectomy (odds ratio, 2.9; 95% confidence interval, 1.23 to 6.78). Patients with HER2neu-positive DCIS had greater extent of disease by imaging and were more likely to undergo mastectomy than HER2neu-negative. These findings will help surgeons counsel patients on surgical treatment.

scholarly journals Cardiotoxicidade nas Terapias Neoadjuvante e Adjuvante do Câncer de Mama

2019 ◽  
Vol 65 (3) ◽  
Author(s):  
Livia Christina de Oliveira Pina ◽  
Flavia Axelband ◽  
Maria Fernanda Barbosa ◽  
Mario Jorge Sobreira da Silva
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Cáncer De Mama ◽  
Evaluation Committee ◽  
Insuficiencia Cardiaca ◽  
Her 2 ◽  
Epidermal Growth

Introdução: O câncer de mama é o mais comum entre as mulheres em todo o mundo, representando quase 25% de todos os casos de câncer. Alguns fármacos possuem características peculiares relacionadas à cardiotoxicidade. Objetivo: Analisar a incidência, as características clínicas e os fatores de risco associados à ocorrência de cardiotoxicidade em pacientes submetidas ao protocolo doxorrubicina e ciclofosfamida seguido ou não de taxanos e naquelas que realizaram o mesmo protocolo associado ao trastuzumabe. Método: Trata-se de um estudo de coorte realizado em um hospital público do Rio de Janeiro. Foram incluídas 153 pacientes que iniciaram tratamento entre os meses de setembro e novembro de 2012. A cardiotoxicidade foi definida com base nos critérios do Cardiac Review and Evaluation Committee e da Sociedade Brasileira de Cardiologia. Foi calculado o risco relativo (RR), utilizando-se um intervalo de confiança (IC) de 95%. Resultados: A incidência de cardiotoxicidade foi de 17%. Observou-se queda da fração de ejeção do ventrículo esquerdo em 31,3% e 52,2% das pacientes nos grupos human epidermal growth factor receptor-type 2 (HER-2) negativo e positivo, respectivamente. Foram identificados três casos de insuficiência cardíaca, sendo dois em pacientes HER-2 positivas. As pacientes que utilizaram trastuzumabe apresentaram maior risco de desenvolver cardiotoxicidade (RR=3,53; IC 95%: 1,84-6,79) em comparação com as mulheres do grupo HER-2 negativo. Conclusão: Foi possível verificar a ocorrência de casos de cardiotoxicidade em ambos os grupos com maior incidência para o grupo HER-2 positivo.

Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian Cancer

2002 ◽  
Vol 85 (2) ◽  
pp. 305-310 ◽  
Author(s):  
G. Ferrandina ◽  
F.O. Ranelletti ◽  
L. Lauriola ◽  
F. Fanfani ◽  
F. Legge ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Cyclooxygenase 2 ◽  
Her 2 ◽  
Epidermal Growth ◽  
Cox 2

scholarly journals Immunohistochemical Staining of Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 in Carcinoma Breast in Bangladeshi Women

2016 ◽  
Vol 11 (1) ◽  
pp. 7-13
Author(s):  
Md Jaynul Islam ◽  
Selina Akhter ◽  
SM Mahbubul Alam ◽  
Md Yousuf Ali ◽  
Shamoli Yesmin
Keyword(s):  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Breast Carcinoma ◽  
Epidermal Growth Factor ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Human Epidermal Growth Factor ◽  
Her 2 ◽  
Epidermal Growth

Introduction: Breast cancer is the most common cause of cancer death among women. Estrogen Receptor (ER), Progesterone Receptor (PR) and human epidermal growth factor receptor 2 (Her-2/ neu) status are used as an important prognostic marker for breast cancer.Objectives: The aim of this study was to evaluate ER and Her-2 in breast carcinoma among Bangladeshi women and to co-relate with other prognostic parameters.Materials and Methods: The study was carried out in a tertiary level hospital in Bangladesh during the period of January 2010 to December 2011. Total 100 histologically proved breast carcinoma cases were included in the study. Immunostaining for ER and Her-2/neu were carried out. Quick scoring of ER and expression of Her-2/neu were correlated with histomorphological parameters.Results: Among 100 cases 93 were ductal carcinoma and 07 were non ductal. Among all, 38% show ER positive (score- 3-8) while 62% are ER negative (score 0-2). Her-2/neu was over expressed in 30%, 22% were borderline and 48% were negative. There were inverse relationship between ER positivity and Her-2/neu overexpression. ER positivity was related with lower histological grade, while Her-2/neu overexpression was related with higher histological grade.Conclusions: ER positivity in Breast carcinoma patients in Bangladesh is lower in comparison to western literature while Her-2/neu overexpression rate is quite high like other Asian countries.Journal of Armed Forces Medical College Bangladesh Vol.11(1) 2015: 7-13

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers

2009 ◽  
Vol 62 (10) ◽  
pp. 926-930 ◽  
Author(s):  
P van der Groep ◽  
P J van Diest ◽  
F H Menko ◽  
J Bart ◽  
E G E de Vries ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Molecular Type ◽  
Mutation Carriers ◽  
Epidermal Growth ◽  
Grade 3

Aims:Ductal carcinoma in situ (DCIS) is an established late precursor of sporadic invasive breast cancer and to a large extent parallels its invasive counterpart with respect to molecular changes and immunophenotype. Invasive breast cancers in germline BRCA1 and BRCA2 mutation carriers have a distinct “basal” and “luminal” immunophenotype, respectively, but the immunophenotype of their precursor lesions has hardly been studied, and this was the aim of this study.Methods:DCIS lesions of 25 proven BRCA1 and 9 proven BRCA2 germline mutation carriers and their 22 and 6, respectively, accompanying invasive lesions were stained by immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER)2/neu, cytokeratin (CK)5/6, CK14, epidermal growth factor receptor (EGFR) and Ki67.Results:DCIS lesions in BRCA1 mutation carriers were mostly of the basal molecular type with low ER/PR/HER2 expression, while they frequently expressed CK5/6, CK14 and EGFR, and were mostly grade 3 and highly proliferative. DCIS lesions in BRCA2 mutation carriers were mostly of luminal molecular type with frequent expression of ER/PR, and infrequent expression of CK5/6, CK14 and EGFR, and they were mostly grade 3 and showed low proliferation. In BRCA1 and BRCA2 mutation carriers there was a high concordance between DCIS lesions and their concomitant invasive counterpart with regard to expression of individual markers as well as “molecular” subtype.Conclusions:Although the number of cases studied was low, DCIS lesions in BRCA1 and BRCA2 mutations carriers are usually of the basal and luminal molecular type, respectively, similar to their accompanying invasive cancers, thereby providing evidence that DCIS is a direct precursor lesion in these hereditary predisposed patients. This also suggests that crucial carcinogenetic events leading to these phenotypes in hereditary predisposed patients occur before the stage of invasion.

Sign in / Sign up

Export Citation Format

Share Document